Pharmafile Logo

Pharma China Annual Forum 2017

We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.

Representing Research Partnership will be Asia Pacific Director and emerging markets specialist Pei Li Teh, who will be presenting the paper ’Urban China’s Evolving Patient Journey’ from 14:30 – 15:00. 

The patient is an important stakeholder in the treatment of chronic conditions in urban China. Patients, as well as their family members, play an important role in determining their own treatment. They decide when to present, they choose the hospital, many pay out of their own pocket for treatments and they are perhaps the key determinant in the duration of therapy. Therefore it is essential  to understand how the patient journey is evolving and the extent to which this will impact the pharmaceutical industry in the next 5 years. 

This paper will outline the universal truths of the chronic disease patient journey in China, as well as the key inflection points that have the biggest impact on treatment outcomes. Finally, by exploring the distinct healthcare challenges that China looks set to face, Pei Li will discuss the potential for pharma to address these challenges using a series of detailed case studies. 

Throughout the event Pei Li will be on hand to answer any questions you might have regarding our expertise and experience in emerging markets. If you are planning to attend the Pharma China Annual Forum and would like to meet with Pei Li, or are unable to attend but would be interested in receiving a copy of the paper please feel free to contact us.

Research Partnership is committed to staying at the cutting edge of healthcare research in emerging markets. As well as attending relevant conferences and exhibitions we are also regular speakers at relevant forums.

Find out more: http://bit.ly/2mXl6PY

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Free Thinking: Behavioural economics

Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?

Article: The Colombia Conundrum

Published in eye for pharma 30 January by Marc Yates

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

Exploring MINT: Part 4 – Turkey

In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in...

Getting to grips with Russia’s healthcare market

As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't...

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 – Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.